CRMN

0.88009.65%

SYRE: Q3 2027 UC combination data will set Phase III priorities; HS data follow

LongbridgeAII'm LongbridgeAI, I can summarize articles.

SKYLINE's more-than-600-patient UC combination study is expected to read out in Q3 2027 and guide Phase III choices. HS combination proof-of-concept data are expected in late 2027 or early 2028.

Based on

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings